{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:12:02Z","timestamp":1773317522813,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00296-020-04659-5","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T08:05:48Z","timestamp":1595750748000},"page":"1941-1947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adrenocorticotropic hormone: an effective \u201cnatural\u201d biologic therapy for acute gout?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-8554","authenticated-orcid":false,"given":"Andrew P.","family":"Andonopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,26]]},"reference":[{"key":"4659_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T (2011) Clinical practice. Gout N Engl J Med 364:443\u2013452","journal-title":"Gout N Engl J Med"},{"key":"4659_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50:S11\u2013S16","journal-title":"Semin Arthritis Rheum"},{"key":"4659_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol Nat Res 16:380\u2013390","journal-title":"Nat Rev Rheumatol Nat Res"},{"key":"4659_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649\u2013662","journal-title":"Nat Rev Rheumatol"},{"key":"4659_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS et al (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124:155\u2013163","journal-title":"Am J Med"},{"key":"4659_CR6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64:1447\u20131461","journal-title":"Arthritis Care Res"},{"key":"4659_CR7","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","volume":"50","author":"MH Pillinger","year":"2020","unstructured":"Pillinger MH, Mandell BF (2020) Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum 50:S24\u201330","journal-title":"Semin Arthritis Rheum"},{"key":"4659_CR8","doi-asserted-by":"crossref","unstructured":"Mouradjian MT, Plazak ME, Gale SE, Noel ZR, Watson K, Devabhakthuni S (2020) Pharmacologic management of gout in patients with cardiovascular disease and heart failure. Am J Cardiovasc Drugs (online ahead of print)","DOI":"10.1007\/s40256-020-00400-6"},{"key":"4659_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P (2017) Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 15:123. https:\/\/doi.org\/10.1186\/s12916-017-0890-9","journal-title":"BMC Med"},{"key":"4659_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75:210\u2013217","journal-title":"Ann Rheum Dis"},{"key":"4659_CR11","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839\u20131848","journal-title":"Ann Rheum Dis"},{"key":"4659_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.semarthrit.2013.09.006","volume":"43","author":"D Daoussis","year":"2014","unstructured":"Daoussis D, Antonopoulos I, Andonopoulos AP (2014) ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action. Semin Arthritis Rheum 43:648\u2013653","journal-title":"Semin Arthritis Rheum"},{"key":"4659_CR13","first-page":"137","volume":"37","author":"MK Nisar","year":"2019","unstructured":"Nisar MK (2019) Crystallising the role of adrenocorticotropic hormone in the management of acute gout: a review. Clin Exp Rheumatol 37:137\u2013145","journal-title":"Clin Exp Rheumatol"},{"key":"4659_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semarthrit.2014.02.003","volume":"44","author":"PP Khanna","year":"2014","unstructured":"Khanna PP, Gladue HS, Singh MK, FitzGerald JD, Bae S, Prakash S et al (2014) Treatment of acute gout: a systematic review. Semin Arthritis Rheum 44:31\u201338","journal-title":"Semin Arthritis Rheum"},{"key":"4659_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2165\/00003495-200868040-00002","volume":"68","author":"N Schlesinger","year":"2008","unstructured":"Schlesinger N (2008) Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs 68:407\u2013415","journal-title":"Drugs"},{"key":"4659_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/14656560902950742","volume":"10","author":"N Schlesinger","year":"2009","unstructured":"Schlesinger N, Dalbeth N, Perez-Ruiz F (2009) Gout-what are the treatment options? Expert Opin Pharmacother 10:1319\u20131328","journal-title":"Expert Opin Pharmacother"},{"key":"4659_CR17","first-page":"365","volume":"35","author":"CT Taylor","year":"2001","unstructured":"Taylor CT, Brooks NC, Kelley KW (2001) Corticotropin for acute management of gout. AnnPharmacother 35:365\u2013368","journal-title":"AnnPharmacother"},{"key":"4659_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jama.1950.02920160001001","volume":"144","author":"PS Hench","year":"1950","unstructured":"Hench PS, Slocumb CH, Polley HF, Kendall EC (1950) Effect of cortisone and pituitary adrenocorticotropic hormone (acth) on rheumatic diseases. J Am Med Assoc 144:1327\u20131335","journal-title":"J Am Med Assoc"},{"key":"4659_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.1780310618","volume":"31","author":"D Axelrod","year":"1988","unstructured":"Axelrod D, Preston S (1988) Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 31:803\u2013805","journal-title":"Arthritis Rheum"},{"key":"4659_CR20","first-page":"1325","volume":"21","author":"LB Siegel","year":"1994","unstructured":"Siegel LB, Alloway JA, Nashel DJ (1994) Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 21:1325\u20131327","journal-title":"J Rheumatol"},{"key":"4659_CR21","first-page":"696","volume":"21","author":"J Ritter","year":"1994","unstructured":"Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H (1994) ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 21:696\u2013699","journal-title":"J Rheumatol"},{"key":"4659_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jbspin.2012.09.009","volume":"80","author":"D Daoussis","year":"2013","unstructured":"Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP (2013) ACTH as first line treatment for acute gout in 181 hospitalized patients. Jt Bone Spine 80:291\u2013294","journal-title":"Jt Bone Spine"},{"key":"4659_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jbspin.2013.05.006","volume":"81","author":"D Daoussis","year":"2013","unstructured":"Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP (2013) ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Jt Bone Spine 81:98\u2013100","journal-title":"Jt Bone Spine"},{"key":"4659_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/1756-185X.12578","volume":"19","author":"NJ Kennedy","year":"2016","unstructured":"Kennedy NJ, Healy PJ, Harrison AA (2016) Inpatient management of gout in a New Zealand hospital: A retrospective audit. Int J Rheum Dis 19:205\u2013210","journal-title":"Int J Rheum Dis"},{"key":"4659_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.31138\/mjr.29.3.178","volume":"29","author":"D Daoussis","year":"2018","unstructured":"Daoussis D, Kordas P (2018) ACTH vs betamethasone for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. Mediterr J Rheumatol 29:178\u2013181","journal-title":"Mediterr J Rheumatol"},{"key":"4659_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fendo.2019.00683","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang W, Guo DY, Lin YJ, Tao YX (2019) Melanocortin regulation of inflammation. Front Endocrinol 10:683","journal-title":"Front Endocrinol"},{"key":"4659_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","volume":"111","author":"SJ Getting","year":"2006","unstructured":"Getting SJ (2006) Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111:1\u201315","journal-title":"Pharmacol Ther"},{"key":"4659_CR28","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.bbadis.2017.03.020","volume":"1863","author":"MD Ericson","year":"2017","unstructured":"Ericson MD, Lensing CJ, Fleming KA, Schlasner KN, Doering SR, Haskell-Luevano C (2017) Bench-top to clinical therapies: a review of melanocortin ligands from 1954 to 2016. Biochim Biophys Acta Mol Basis Dis 1863:2414\u20132435","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4659_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11926-011-0163-0","volume":"13","author":"T Montero-Melendez","year":"2011","unstructured":"Montero-Melendez T, Patel HB, Perretti M (2011) Role of melanocortin receptors in the regulation of gouty inflammation. Curr Rheumatol Rep 13:138\u2013145","journal-title":"Curr Rheumatol Rep"},{"key":"4659_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1210\/er.2006-0034","volume":"27","author":"RD Cone","year":"2006","unstructured":"Cone RD (2006) Studies on the physiological functions of the melanocortin system. Endocr Rev Endocr Soc 27:736\u2013749","journal-title":"Endocr Rev Endocr Soc"},{"key":"4659_CR31","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.4049\/jimmunol.161.6.2873","volume":"161","author":"SK Manna","year":"1998","unstructured":"Manna SK, Aggarwal BB (1998) Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 161:2873\u20132880","journal-title":"J Immunol"},{"key":"4659_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2007-0027","volume":"29","author":"T Brzoska","year":"2008","unstructured":"Brzoska T, Luger TA, Maaser C, Abels C, Bohm M (2008) Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 29:581\u2013602","journal-title":"Endocr Rev"},{"key":"4659_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.peptides.2005.01.031","volume":"27","author":"CW Lam","year":"2006","unstructured":"Lam CW, Perretti M, Getting SJ (2006) Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides 27:404\u2013412","journal-title":"Peptides"},{"key":"4659_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1749-6632.1999.tb08682.x","volume":"885","author":"DH Kalden","year":"1999","unstructured":"Kalden DH, Scholzen T, Brzoska T, Luger TA (1999) Mechanisms of the antiinflammatory effects of alpha-MSH. Role of transcription factor NF-kappa B and adhesion molecule expression. Ann N YAcad Sci 885:254\u2013261","journal-title":"Ann N YAcad Sci"},{"key":"4659_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1210\/en.2002-220651","volume":"144","author":"TE Scholzen","year":"2003","unstructured":"Scholzen TE, Sunderkotter C, Kalden DH, Brzoska T, Fastrich M, Fisbeck T et al (2003) Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144:360\u2013370","journal-title":"Endocrinology"},{"key":"4659_CR36","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.162.12.7446","volume":"162","author":"SJ Getting","year":"1999","unstructured":"Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti M (1999) POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 162:7446\u20137453","journal-title":"J Immunol"},{"key":"4659_CR37","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/art.10526","volume":"46","author":"SJ Getting","year":"2002","unstructured":"Getting SJ, Christian HC, Flower RJ, Perretti M (2002) Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 46:2765\u20132775","journal-title":"Arthritis Rheum"},{"key":"4659_CR38","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar2827","volume":"11","author":"F Capsoni","year":"2009","unstructured":"Capsoni F, Ongari AM, Reali E, Catania A (2009) Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther 11:R151","journal-title":"Arthritis Res Ther"},{"key":"4659_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"4659_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/985815","author":"TJ Ahmed","year":"2013","unstructured":"Ahmed TJ, Montero-Melendez T, Perretti M, Pitzalis C (2013) Curbing inflammation through endogenous pathways: focus on melanocortin peptides. Int J Inflam. https:\/\/doi.org\/10.1155\/2013\/985815","journal-title":"Int J Inflam"},{"key":"4659_CR41","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.4049\/jimmunol.137.7.2232","volume":"137","author":"JG Cannon","year":"1986","unstructured":"Cannon JG, Tatro JB, Reichlin S, Dinarello CA (1986) Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. J Immunol 137:2232\u20132236","journal-title":"J Immunol"},{"key":"4659_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0014-2999(91)90514-Q","volume":"197","author":"KG Mugridge","year":"1991","unstructured":"Mugridge KG, Perretti M, Ghiara P, Parente L (1991) Alpha-melanocyte-stimulating hormone reduces interleukin-1 beta effects on rat stomach preparations possibly through interference with a type I receptor. Eur J Pharmacol 197:151\u2013155","journal-title":"Eur J Pharmacol"},{"key":"4659_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1476-5381.1992.tb14361.x","volume":"106","author":"S Poole","year":"1992","unstructured":"Poole S, Bristow AF, Lorenzetti BB, Das RE, Smith TW, Ferreira SH (1992) Peripheral analgesic activities of peptides related to alpha-melanocyte stimulating hormone and interleukin-1 beta 193\u2013195. Br J Pharmacol 106:489\u2013492","journal-title":"Br J Pharmacol"},{"key":"4659_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1749-6632.1999.tb08680.x","volume":"885","author":"T Brzoska","year":"1999","unstructured":"Brzoska T, Kalden DH, Scholzen T, Luger TA (1999) Molecular basis of the alpha-MSH\/IL-1 antagonism. Ann N Y Acad Sci 885:230\u2013238","journal-title":"Ann N Y Acad Sci"},{"key":"4659_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0014-2999(92)90738-P","volume":"220","author":"Y Uehara","year":"1992","unstructured":"Uehara Y, Shimizu H, Sato N, Tanaka Y, Shimomura Y, Mori M (1992) Carboxyl-terminal tripeptide of alpha-melanocyte-stimulating hormone antagonizes interleukin-1-induced anorexia. Eur J Pharmacol 220:119\u2013122","journal-title":"Eur J Pharmacol"},{"key":"4659_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/jpet.103.051623","volume":"306","author":"SJ Getting","year":"2003","unstructured":"Getting SJ, Schioth HB, Perretti M (2003) Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 306:631\u2013637","journal-title":"J Pharmacol Exp Ther"},{"key":"4659_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29\u201342","journal-title":"Ann Rheum Dis"},{"key":"4659_CR48","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al (2012) 2012 American college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431\u20131446","journal-title":"Arthritis Care Res"},{"key":"4659_CR49","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res 72:744\u2013760","journal-title":"Arthritis Care Res"},{"key":"4659_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","volume":"47","author":"C Ponticelli","year":"2006","unstructured":"Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S et al (2006) A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47:233\u2013240","journal-title":"Am J Kidney Dis"},{"key":"4659_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0074-7742(02)49013-7","volume":"49","author":"KL Brunson","year":"2002","unstructured":"Brunson KL, Avishai-Eliner S, Baram TZ (2002) ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol 49:185\u2013197","journal-title":"Int Rev Neurobiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04659-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T21:20:35Z","timestamp":1696454435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,26]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4659"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04659-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,26]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DD has received speaking fees and honorarium for participation in the advisory board from Mallinckrodt. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review article. This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}